Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to VEGF to inhibit its binding to the cell surface VEGF receptors for both the tumor cells as well as the local healthy cells [31]. The gene discussed is VEGFA; the disease is neoplasm.